Novoron Bioscience Wins $2.5 Million NIH Grant to Advance Human Organoid Platform for Alzheimer’s Drug Discovery

New updates have been reported about Novoron Bioscience.

Novoron Bioscience has secured a $2.5 million Small Business Innovation Research grant from the National Institute on Aging, providing non-dilutive capital to advance its human brain organoid platform for Alzheimer’s drug discovery. The San Diego-based biotech will use the funding to validate a high-throughput screening system built on human iPSC-derived cortical organoids that better replicate human brain circuitry and cell–cell interactions than traditional 2D cultures or animal models, with the goal of identifying compounds that block tau propagation, a key driver of Alzheimer’s disease progression. Planned milestones include establishing functional and molecular readouts relevant to tau spread, executing a benchmarking screen of roughly 3,096 FDA-approved compounds, and applying transcriptomic and AI-based analytics to prioritize candidates based on efficacy and safety. CEO and CSO Travis Stiles, PhD, said the platform is designed to generate decision-grade data that can support rapid progression into IND-enabling studies.

Strategically, the grant enables Novoron to de-risk its Alzheimer’s pipeline and strengthen its partnering position by producing robust data packages aligned with pharmaceutical due diligence requirements. A central focus of the program is LRP1, a receptor implicated in synaptic tau propagation, where Novoron has already demonstrated that its LRP1 antagonist NOVO118 can reduce tau spread and has identified a druggable binding pocket suitable for selective small-molecule inhibitor design. The organoid system’s 384-well format allows true high-throughput screening, potentially shortening timelines and improving prediction of clinical success relative to legacy models. Awarded under Grant Number R44AG097355 in September 2025, the project is expected to deliver several inflection points, including full platform validation and nomination of lead candidates for further development, reinforcing Novoron’s broader strategy to develop targeted therapeutics for Alzheimer’s disease, related tauopathies, and neurological injury through modulation of the low-density lipoprotein receptor family pathways.